Home > Focus Areas > DLBCL Connect > Post
4yr
Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma
Source : https://www.nature.com/articles/s41598-020-80376-0
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease whose prognosis is associated with clinical features, cell-of-origin and genetic aberrations. Recent integrative, multi-omic analyses had led to identifying overlapping genetic DLBCL subtypes. We used targeted massive sequencing to analyze 84 diagnostic samples from a multicenter cohort of patients with DLBCL treated with rituximab-containing therapies and a median follow-up of 6 years.
-
Mark Fesler4yrCurrently, there are no readily available platforms of molecular testing that inform the clinical care of DLBCL. I hope that this article inches the field a step closer to making this a possibility someday.